Diego Díaz García/X
Jun 9, 2025, 07:29
Diego Díaz García Highlights LAG-3 as Emerging Checkpoint Target in Melanoma
Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:
“Emerging checkpoint target: LAG-3.
Combining relatlimab (anti–LAG-3) with nivolumab enhances efficacy in melanoma vs. PD-1 alone, potentially with less toxicity than CTLA-4 combos. New frontiers in solid tumors are opening.”
Title: The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies
Authors: Vinay K. Giri, David F. McDermott, Jacob Zaemes
Read The Full Article at ACS Journal.
More posts featuring Diego Díaz García.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 15:02
Aug 18, 2025, 14:54
Aug 18, 2025, 14:54
Aug 18, 2025, 14:47